, Volume 115, Issue 4, pp 454–462 | Cite as

Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole

  • Paul Willner
  • Spiros Lappas
  • Survjit Cheeta
  • Richard Muscat
Original Investigations


Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of a palatable (1%) sucrose solution, and to attenuate food-induced place preference conditioning. In this study the effects of pramipexole (SND-919), a dopamine D2 agonist, were studied during 7–9 weeks of chronic treatment. Pramipexole (1.0 mg/kg per day) reversed the suppression of sucrose intake in stressed animals, increasing sucrose intakes above the levels seen in untreated nonstressed controls. Pramipexole also increased sucrose intake in nonstressed animals; these effects were accompanied by increases in water intake and tended to correlate with weight loss. Drug-treated stressed animals also lost weight, but in this case water intake was unaffected. A second group of animals received a higher dose of pramipexole (2.0 mg/kg per day). The effects of the two doses were very similar. After three weeks of treatment, these animals were switched to a lower dose of pramipexole (0.1 mg/kg per day). Increases in sucrose intake were maintained over three weeks of treatment at the lower dose, with significant recovery of body weight. Two further groups received the same doses of pramipexole (1.0 mg/kg for 6 weeks or 2.0 mg/kg for 3 weeks followed by 0.1 mg/kg thereafter), but received intermittent (twice-weekly) drug treatment. Intermittent pramipexole treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Following 6–8 weeks of pramipexole treatment, food-induced place preference conditioning was studied in all animals. Untreated stressed animals showed no evidence of place conditioning. Normal conditioning was seen in both groups of stressed animals treated daily with pramipexole (at 1.0 and 0.1 mg/kg) and in the group treated twice weekly at the higher dose (1.0 mg/kg); intermittent treatment at the lower dose (0.1 mg/kg) was ineffective. The results indicate that pramipexole exerts rapid anti-anhedonic effects in the chronic mild stress model. This conclusion is complicated, but not undermined, by drug-induced weight loss and by the presence of significant drug effects in nonstressed control animals.

Key words

Stress Sucrose drinking Place preference conditioning Reward Pramipexole D2 agonist Rats 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ayd FJ, Zohar J (1987) Psychostimulant (amphetamine or methylphenidate) therapy for chronic and treatment-resistant depression. In: Zohar J, Belmaker RH (eds) Treating resistant depression. PMA Publishing Corp., New York, pp 343–355Google Scholar
  2. Bozarth MA (1987) Conditioned place preference: a parametric analysis using systemic heroin injections. In: Bozarth MA (ed) Methods of assessing the reinforcing properties of abused drugs. Springer, Heidelberg, pp 241–273Google Scholar
  3. Cheeta S, Broekkamp CLE, Willner P (1994) Stereospecific reversal of stress-induced anhedonia by mianserin and its (+)-enantiomer. Psychopharmacology, in pressGoogle Scholar
  4. Delina-Stula A, Radeke E, Van Riezen H (1988) Enhanced functional responsiveness of the dopaminergic system: The mechanism of anti-immobility effects of antidepressants in the behavioural despair test in the rat. Neuropharmacology 27:943–947Google Scholar
  5. Fawcett J, Clark DC, Scheftner WA, Gibbons RD (1983) Assessing anhedonia in psychiatric patients: The pleasure scale. Arch Gen Psychiatry 40:79–84Google Scholar
  6. Klein DF (1974) Endogenomorphic depression: a conceptual and terminological revision Arch Gen Psychiatry 31:447–454Google Scholar
  7. Klimek V, Maj J (1989) Repeated administration of antidepressant drugs enhanced agonist affinity for mesolimbic D-2 receptors. J Pharm Pharmacol 41:555–558Google Scholar
  8. Maj J (1988) Repeated treatment with antidepressant drugs and functional changes of catecholaminergic receptors at the behavioural level. In: Belmaker RH, Sandler M, Dahlstrom A (eds) Progress in catecholamine research: part C, clinical aspects. Liss, New York, pp 255–261Google Scholar
  9. Mierau J, Schingnitz G (1992) Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 215:161–170Google Scholar
  10. Moreau J-L, Jenck F, Martin JR, Mortas P, Haefely WE (1992) Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmental self-stimulation behavior in rats. Eur Neuropsychopharmacol 2:43–49Google Scholar
  11. Moreau J-L, Jenck F, Martin JR, Mortas P, Haefely WE (1993) Effects of moclobemide, a new generation reversible MAO-A inhibitor in a novel animal model of depression. Pharmacopsychiatry 26:30–33Google Scholar
  12. Mouret J, LeMoine P, Minuit M (1987) Marqueurs polygraphiques, cliniques et therapeutiques des depressions dopamino-dependantes (DDD). Comptes Rend l'Academie de Science, Paris, 305 [Serie III]:301–306Google Scholar
  13. Muscat R, Willner P (1992) Suppression of sucrose drinking by chronic mild unpredictable stress: a methodological analysis. Neurosci Biobehav Rev 16:507–517Google Scholar
  14. Muscat R, Towell A, Willner P (1988) Changes in dopamine autoreceptor sensitivity in an animal model of depression. Psychopharmacology 94:545–550Google Scholar
  15. Muscat R, Sampson D, Willner P (1990) Dopaminergic mechanism of imipramine action in an animal model of depression. Biol Psychiatry 28:223–230Google Scholar
  16. Muscat R, Papp M, Willner P (1992a) Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology 109:433–438Google Scholar
  17. Muscat R, Papp M, Willner P (1992b) Antidepressant-like actions of dopamine agonists in an animal model of depression. Biol Psychiatry 31:937–946Google Scholar
  18. Papp M, Willner P (1991) 8-OH-DPAT-induced place preference and place aversion: effects of PCPA and dopamine antagonists. Psychopharmacology 103:99–102Google Scholar
  19. Papp M, Willner P, Muscat R (1991) An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology 104:255–259Google Scholar
  20. Papp M, Lappas S, Muscat R, Willner P (1992) Attenuation of place preference conditioning but not place aversion conditioning by chronic mild stress. J Psychopharmacol 6:352–356Google Scholar
  21. Papp M, Muscat R, Willner P (1993a) Subsensitivity to rewarding and locomotor stimulant effects of a dopamine agonist following chronic mild stress. Psychopharmacology 110:152–158Google Scholar
  22. Papp M, Muscat R, Willner P (1993b) Behavioural sensitization to a dopamine agonist is associated with recovery from stress-induced anhedonia. Psychopharmacology 110:159–164Google Scholar
  23. Plaznik A, Kostowski W (1987) The effects of antidepressants and electroconvulsive shocks on the function of the mesolimbic dopamine system: a behavioural study. Eur J Pharmacol 135:389–396Google Scholar
  24. Post RM, Gerner RH, Carman JS, Gillin JC, Jimerson DC, Goodwin FK, Bunney WE (1978) Effects of a dopamine agonist piribedil in depressed patients. Arch Gen Psychiatry 35:609–615Google Scholar
  25. Reus VI, Lake CR, Post RM (1980) Effect of piribedil (ET-495) on plasma norepinephrine: Relationship to antidepressant response. Commun Psychopharmacol 4:207–213Google Scholar
  26. Sampson D, Muscat R, Willner P (1991) Reversal of antidepressant action by dopamine antagonists in an animal model of depression. Psychopharmacology 104:491–495Google Scholar
  27. Schneider CS, Mierau J (1987) Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahy-drobenzothiazole and an aminothiazole analogue of apomorphine. J Med Chem 30:494–498Google Scholar
  28. Serra G, Collu M, D'Aquila PS, de Montis GM, Gessa G (1990) Possible role of dopamine D1 receptor in the behavioural subsensitivity to dopamine agonists induced by chronic treatment with antidepressants. Brain Res 527:234–243Google Scholar
  29. Shopsin B, Gershon S (1978) Dopamine receptor stimulation in the treatment of depression: piribedil (ET-495) Neuropsychobiology 4:1–14Google Scholar
  30. Stamford JA, Muscat R, O'Connor JJ, Patel JJ, Wieczorek WJ, Kruk ZL, Willner P (1991) Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine. Psychopharmacology 105:275–282Google Scholar
  31. Theohar C, Fischer-Cornellson K, Akesson HO, Ansari J, Gerlach G, Ohman R, Ose E, Stegink AJ (1981) Bromocriptine as antidepressant: double-blind comparative study with imipramine in psychogenic and endogenous depression. Curr Ther Res 30:830–842Google Scholar
  32. Van der Kooy D (1987) Place conditioning: a simple and effective method for assessing the motivational properties of drugs. In: Bozarth MA (ed) Methods of assessing the reinforcing properties of abused drugs. Springer, Heidelburg, pp 229–240Google Scholar
  33. Waehrens J, Gerlach J (1981) Bromocriptine and imipramine in endogenous depression: a double-blind controlled trial in outpatients. J Affect Disord 3:193–202Google Scholar
  34. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987) Reduction of sucrose preference by chronic mild stress and its restoration by a tricyclic antidepressant. Psychopharmacology 93:358–364Google Scholar
  35. Willner P, Klimek V, Golembiowska K, Muscat R (1991a) Changes in mesolimbic dopamine may explain stress-induced anhedonia. Psychobiology 19:79–84Google Scholar
  36. Willner P, Sampson D, Papp M, Phillips G, Muscat R (1991b) Animal models of anhedonia. In: Simon P, Soubrie P, Widlocher D (eds) Animal models of psychiatric disorders, vol 3. Karger, Basel, pp 71–99Google Scholar
  37. Winer BJ (1971) Statistical principles in experimental design. McGraw Hill, LondonGoogle Scholar
  38. Zacharko RM, Anisman H (1991) Stressor-provoked alterations of intracranial self-stimulation in the mesocortiolimbic dopamine system: an animal model of depression In: Willner P, Scheel-Kruger J (eds) The mesolimbic dopamine system, from motivation to Action. Wiley, Chichester, pp 411–442Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Paul Willner
    • 1
  • Spiros Lappas
    • 1
  • Survjit Cheeta
    • 1
  • Richard Muscat
    • 1
  1. 1.Department of PsychologyCity of London PolytechnicLondonUK

Personalised recommendations